Tudor Investment Corp Et Al Acquires 66,115 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Tudor Investment Corp Et Al raised its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) by 150.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 110,121 shares of the biotechnology company’s stock after buying an additional 66,115 shares during the quarter. Tudor Investment Corp Et Al owned 0.09% of Heron Therapeutics worth $465,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in HRTX. Point72 Hong Kong Ltd acquired a new stake in shares of Heron Therapeutics in the 1st quarter valued at $48,000. Captrust Financial Advisors boosted its stake in shares of Heron Therapeutics by 1,539.5% in the 2nd quarter. Captrust Financial Advisors now owns 17,789 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 16,704 shares in the last quarter. Centiva Capital LP acquired a new stake in shares of Heron Therapeutics in the 3rd quarter valued at $59,000. Bridgefront Capital LLC acquired a new stake in shares of Heron Therapeutics in the 1st quarter valued at $60,000. Finally, Quent Capital LLC acquired a new stake in shares of Heron Therapeutics in the 3rd quarter valued at $68,000.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $2.38 on Wednesday. The company has a current ratio of 2.38, a quick ratio of 1.83 and a debt-to-equity ratio of 6.65. Heron Therapeutics, Inc. has a 1 year low of $2.19 and a 1 year high of $6.38. The company has a market cap of $282.96 million, a PE ratio of -1.13 and a beta of 0.86. The company’s 50-day moving average is $2.68 and its two-hundred day moving average is $3.29.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. StockNews.com upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 17th. Needham & Company LLC reduced their price target on shares of Heron Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 9th. Finally, Evercore ISI reduced their price target on shares of Heron Therapeutics to $15.00 in a research report on Tuesday, November 15th.

About Heron Therapeutics

(Get Rating)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.